Azora Therapeutics Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
Azora Therapeutics General Information
Description
Developer of a therapeutic medicine intended to treat serious, debilitating inflammatory diseases. The company specializes in developing novel small-molecule new chemical entities for the treatment of autoimmune and inflammatory diseases like hidradenitis suppurativa and ulcerative colitis, enabling patients to get improved treatment against such diseases.
Contact Information
Website
www.azoratherapeutics.comCorporate Office
- 4267 Valley Meadow Road
- Encino, CA 91436
- United States
Corporate Office
- 4267 Valley Meadow Road
- Encino, CA 91436
- United States
Azora Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 11-Jun-2026 | Completed | Clinical Trials - Phase 1 | |||
| 2. Later Stage VC | 08-Aug-2023 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC (Series A) | 11-Jun-2021 | $7.73M | $7.73M | Completed | Pre-Clinical Trials |
Azora Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-2 | ||||||||
| Series A-1 |
Azora Therapeutics Patents
Azora Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4493930-A1 | Companion diagnostics and strategies for treatment with an aryl hydrocarbon receptor agonist compound | Inactive | 17-Mar-2022 | ||
| US-20250195469-A1 | Companion diagnostics and strategies for treatment with an aryl hydrocarbon receptor agonist compound | Pending | 17-Mar-2022 | ||
| WO-2023178288-A1 | Companion diagnostics and strategies for treatment with an aryl hydrocarbon receptor agonist compound | Inactive | 17-Mar-2022 | ||
| AU-2022360542-A1 | Derivatives of aryl hydrocarbon receptor agonists | Pending | 08-Oct-2021 | ||
| CA-3233526-A1 | Derivatives of aryl hydrocarbon receptor agonists | Pending | 08-Oct-2021 | C07D209/36 |
Azora Therapeutics Signals
Azora Therapeutics Former Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 7G Bioventures | Venture Capital | Minority | ||
| Floating Point (Boston) | Venture Capital | Minority | ||
| Tarnagulla Ventures | Venture Capital | Minority |
Azora Therapeutics FAQs
-
When was Azora Therapeutics founded?
Azora Therapeutics was founded in 2017.
-
Where is Azora Therapeutics headquartered?
Azora Therapeutics is headquartered in Encino, CA.
-
What is the size of Azora Therapeutics?
Azora Therapeutics has 2 total employees.
-
What industry is Azora Therapeutics in?
Azora Therapeutics’s primary industry is Drug Discovery.
-
Is Azora Therapeutics a private or public company?
Azora Therapeutics is a Private company.
-
What is Azora Therapeutics’s current revenue?
The current revenue for Azora Therapeutics is .
-
How much funding has Azora Therapeutics raised over time?
Azora Therapeutics has raised $8.32M.
-
Who are Azora Therapeutics’s investors?
7G Bioventures, Floating Point (Boston), and Tarnagulla Ventures have invested in Azora Therapeutics.
-
When was Azora Therapeutics acquired?
Azora Therapeutics was acquired on 11-Jun-2026.
-
Who acquired Azora Therapeutics?
Azora Therapeutics was acquired by Adial Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process